Nov 13, 2019
Funding from Innovate UK for needle-free solid dose technology
Enesi Pharma secures Innovate UK Funding to enable scalable aseptic manufacturing of ImplaVax®-enabled solid dose viral vector vaccines.

Enesi Pharma, the innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, is delighted to announce that it has secured substantial funding from Innovate UK, the UK's innovation agency, under the Biomedical Catalyst 2019 Round 1: Early and Late Stage Awards Initiative.

The award of £870,419 will co-fund a major new £1.24 million project to develop a scalable aseptic manufacturing process for live or live-attenuated viral vectors for use with Enesi's ImplaVax® needle-free solid dose technology.

See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)